Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24174401 | 0.82 | ADORA2A (0.54) | ADORA2AADORA1PDE7APDE4BPDE7B | |
| SCHEMBL24944131 | 0.78 | LMNA (0.33) | ADORA2AADORA1ELANE | |
| SCHEMBL20618771 | 0.78 | — | — | |
| SCHEMBL24943858 | 0.74 | ALDH1A1 (0.41) | ADORA2AL3MBTL1 | |
| SCHEMBL18924297 | 0.74 | AXL (0.45) | ADORA2AADORA1PDE7APDE4BPDE7B | |
| SCHEMBL14511639 | 0.73 | ADORA2A (0.54) | ADORA2AADORA1PDE7APDE4BPDE4A | |
| SCHEMBL21101027 | 0.72 | USP2 (0.31) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL10139170 | 0.71 | ADORA2A (0.58) | ADORA2AADORA1PDE7AADORA3ADORA2B | |
| SCHEMBL24170309 | 0.69 | ADORA2A (0.56) | ADORA2AADORA1PDE7AADORA2B | |
| SCHEMBL18701478 | 0.69 | ADORA2A (0.56) | ADORA2AADORA1PDE7AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329282-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof | ROCK1, RHOA, ROCK2 | ADORA2A 3025/4885ADORA1 3254/4885PDE7A 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.